The RNA signatures obtained from our randomly selected first cohort of clinical urine samples were promising in that they could detect cancer in four out of five pre-op specimens based on the six known prostate cancer markers including PCA3, the current urine-based marker. The gene discussed is PCA3; the disease is prostate cancer.